Skip to main content

Table 2 Full exclusion criteria

From: A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4–6 μg/kg) in patients with major depressive disorder

 

Exclusion criteria

Consent/communication

Inability to speak or read English

Mental health

 Lifetime

History of psychotic disorder

 Current

Any unstable medical or neurologic condition, judged at the discretion of the clinician

Imminent risk of suicide as determined by the MADRS/clinical interview

Substance abuse or dependence in previous 3 months

Stage 3 treatment-resistant depression or higher as determined by Thase and Rush Staging criteria [21]

Receiving neuromodulation treatment

Undergoing planned changes to psychotropic medication

Drug contraindications

Significant renal or hepatic impairment

Cardiovascular conditions including abnormal heart rate and blood pressure checked at screening

Glaucoma

Female participants who are pregnant, lactating, or planning pregnancy during the course of the trial

Contraindication to the use of scopolamine or glycopyrrolate according to manufacturer guidelines

Regular use of any medication deemed to be contraindicated as judged by the attending study physicians

Other safety criteria

Inability to fast for 2 hours prior to each administration of trial drug

Any other condition judged by the study clinicians as likely to impact on the ability of the participant to complete the trial

Are currently attending a New Zealand specialist mental health or addiction service